Monthly Portfolio Review: August 2026
August was a reminder that a concentrated portfolio can make a month look straightforward in retrospect while feeling anything but straightforward in real time.
This is a retrospective record of the IBKR ISA only. It does not include the separate Trading 212 High Growth Challenge, and it is not a model portfolio or a recommendation to copy any holding.
Portfolio snapshot
| Snapshot | IBKR ISA value |
|---|---|
| 31 July 2026 | £194,538.84 |
| 31 August 2026 | £222,930.28 |
| Change in displayed account value | +£28,391.44 (+14.59%) |
That change is not presented as an investment return. It is the change in the tracked account value between the two month-end snapshots, without a full cash-flow attribution. The end-of-month record also matters more than a good-looking moment during the month.
On 25 August, I shared an IBKR screenshot on X showing £229,185.80 and a strong month-to-date move. The validated 31 August snapshot was lower at £222,930.28. That is a small but useful illustration of the point: a concentrated account can move enough in a few sessions to change the emotional story you tell yourself about the month.
What the portfolio looked like
The core stayed concentrated. The 31 August snapshot recorded 2,000 Rocket Lab shares, 250 Palantir shares, 2,001 AbCellera shares and 1,000 BETA Technologies shares. Smaller positions included 18,000 Surf Air Mobility shares, 80 Strategy shares, 1,000 QYLP units and several higher-risk satellite holdings.
I am deliberately not converting every native-currency position into a headline weighting here. The point of a monthly review is to record the shape of the decision, not manufacture more precision than the source data supports.
What I was watching
- Whether the concentration that created the upside would remain tolerable when the direction reversed.
- Whether I could distinguish a genuine thesis change from the discomfort of a volatile screen.
- Whether the portfolio was still serving the wider aim of freedom, rather than becoming a new source of compulsive monitoring.
Where I could be wrong
A small number of growth companies can create a result that looks rational while prices rise and fragile when sentiment changes. Execution risk, financing risk, dilution and valuation compression remain real. The lesson is not that concentration is automatically wrong. It is that concentration asks more of the investor than a good month can reveal.
See the live Portfolio, the previous July 2026 review, and the relevant company writing through the RKLB archive.